Mark Lewis: RAS(ON) inhibitor responses in pancreatic adenocarcinoma

Mark Lewis posted the following on X:

“Per Ignacio Garrido-Laguna, RMC-6236, a RAS(ON) multiselective inhibitor, can induce responses across a variety of KRAS mutations even in heavily pretreated patients with pancreatic adenocarcinoma!”

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.